Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celldex Therapeutics, Inc.CLDX · Entity 4208 | Director | June 25, 2026 | June 29, 2026 |
| GLAUKOS CorpGKOS · Entity 3510 | Director | May 28, 2026 | June 23, 2026 |
| Seaport Therapeutics, Inc.SPTX · Entity 4799 | Director | April 30, 2026 | May 04, 2026 |
| Surface Oncology, Inc.SURF · Entity 109857 | Director | June 08, 2022 | June 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celldex Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.09 · Expires 2036-06-25 | Direct | 26,000 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 26,000 · Balance 26,000 F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
GLAUKOS Corp
Report date May 28, 2026 · Filed June 23, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.52 · Expires 2036-05-28 | Direct | 2,987 |
Reported balance
After 2026-05-28 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 2,987 · Balance 2,987 F1: This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above. F2: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above.
F2: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date.
Seaport Therapeutics, Inc.
Report date April 30, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Denice M. Torres Revocable Trust | 13,406 |
Reported balance
After 2026-05-04 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-05-04 · Conversion · Acquired 13,406 · Balance 13,406 F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-one basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering on May 4, 2026 without payment of further consideration. The Preferred Stock had no expiration date. F2: The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-29 | Direct | 12,258 |
Reported balance
After 2026-04-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-30 · Grant · Acquired 12,258 · Balance 12,258 F3: The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Denice M. Torres Revocable Trust | 0 |
Reported balance
After 2026-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-04 · Conversion · Disposed 42,105 · Balance 0 F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-one basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering on May 4, 2026 without payment of further consideration. The Preferred Stock had no expiration date. F2: The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-one basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering on May 4, 2026 without payment of further consideration. The Preferred Stock had no expiration date.
F2: The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F3: The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date.
Surface Oncology, Inc.
Report date June 08, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2032-06-08 | Direct | 24,000 |
Reported balance
After 2022-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-08 · Grant · Acquired 24,000 · Balance 24,000 F1: The Options shall vest in twelve equal monthly installments following the date of grant or, if earlier, upon the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: The Options shall vest in twelve equal monthly installments following the date of grant or, if earlier, upon the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
2seventy bio, Inc.
Report date May 13, 2025 · Filed May 15, 2025
Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-05-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-13 · Disposition to issuer · Disposed 12,050 · Balance 19,510 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Row 2 · 2025-05-13 · Other · Disposed 19,510 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2025-05-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-13 · Disposition to issuer · Disposed 24,100 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.
F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration.
Karuna Therapeutics, Inc.
Report date March 18, 2024 · Filed March 18, 2024
Section 16 reporting ended · disclosed 2024-03-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 1
1 source rowRow 1 · 2024-03-18 · Disposition to issuer · Disposed 990 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F2: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $104.26 · Expires 2030-12-21 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-18 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.01 · Expires 2031-06-15 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-18 · Disposition to issuer · Disposed 8,500 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.96 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-18 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $237.70 · Expires 2033-06-19 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-03-18 · Disposition to issuer · Disposed 1,904 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F5: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
F2: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.
F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.
F4: These Options are fully vested.
F5: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date.
bluebird bio, Inc.
Report date November 11, 2021 · Filed November 17, 2021
Section 16 reporting ended · disclosed 2021-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,726 |
Reported balance
After 2021-11-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-11-11 · Other · Acquired 1,476 · Balance 2,726 F1: Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on August 10, 2020 and vests ratably over three years in annual installments commencing on August 10, 2021. F2: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. |
| Common StockSEC Table I · non-derivative | Direct | 2,726 |
Reported balance
After 2021-11-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-11-11 · Other · Acquired 0 · Balance 2,726 F2: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. F4: Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.76 · Expires 2030-08-10 | Direct | 4,430 |
Reported balance
After 2021-11-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-11 · Disposition to issuer · Disposed 4,500 · Balance 4,430 F5: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on August 10, 2020 and vests ratably over three years in annual installments commencing on August 10, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2031-06-15 | Direct | 0 |
Reported balance
After 2021-11-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F6: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on August 10, 2020 and vests ratably over three years in annual installments commencing on August 10, 2021.
F2: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP").
F3: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP.
F4: Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders.
F5: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on August 10, 2020 and vests ratably over three years in annual installments commencing on August 10, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
F6: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 20:12 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001820278-26-000008 · form4-06292026_080636.xml · derivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 22:20 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantStock Option (Right to Buy) · Derivative | 2,987 | $0.00 Strike: $53.57 | $0.00 |
DisclosureSEC source: 0001820278-26-000004 · form4-06012026_100657.xml · derivative · entry 2 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,987 Underlying: Common Stock · 2,987 shares Expires 2036-05-28 F3 · derivative.exercise_date: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 22:20 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001820278-26-000004 · form4-06012026_100657.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,212 F1 · shares: Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 4,609 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| May 28, 2026 Filed Jun 23, 2026 23:22 UTC Amendment | GLAUKOS Corp GKOS · Entity 3510 | GrantStock Option (Right to Buy) · Derivative | 2,987 | $0.00 Strike: $106.52 | $0.00 |
DisclosureSEC source: 0001820278-26-000006 · form4a-06232026_110610.xml · derivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,987 Underlying: Common Stock · 2,987 shares Expires 2036-05-28 F1 · derivative.exercise_price: This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above. F2 · derivative.exercise_date: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date. Read SEC document |
| May 04, 2026 Filed May 4, 2026 22:06 UTC | Seaport Therapeutics, Inc. SPTX · Entity 4799 | ConversionSeries B Preferred Stock · Derivative | 42,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-204468 · ownership.xml · derivative · entry 3 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Denice M. Torres Revocable Trust Disclosed balance after: 0 Underlying: Common Stock · 13,406 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-one basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering on May 4, 2026 without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-one basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering on May 4, 2026 without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-one basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering on May 4, 2026 without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| May 04, 2026 Filed May 4, 2026 22:06 UTC | Seaport Therapeutics, Inc. SPTX · Entity 4799 | ConversionCommon Stock | 13,406 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-204468 · ownership.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Denice M. Torres Revocable Trust Disclosed balance after: 13,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-one basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering on May 4, 2026 without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| April 30, 2026 Filed May 4, 2026 22:06 UTC | Seaport Therapeutics, Inc. SPTX · Entity 4799 | GrantStock Option (Right to Buy) · Derivative | 12,258 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001193125-26-204468 · ownership.xml · derivative · entry 2 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,258 Underlying: Common Stock · 12,258 shares Expires 2036-04-29 F3 · derivative.exercise_date: The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 8, 2026 00:16 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 623 | $0.00 | $0.00 |
DisclosureSEC source: 0001820278-26-000002 · form4-01082026_120123.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,334 F1 · shares: Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes2,731 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:12 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 33,000 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016226 · form4-06092025_080642.xml · derivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: Such option vests in three equal annual installments beginning June 5, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:41 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantStock Option (Right to Buy) · Derivative | 3,149 | $0.00 Strike: $94.87 | $0.00 |
DisclosureSEC source: 0001415889-25-015167 · form4-06022025_080616.xml · derivative · entry 3 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,149 Underlying: Common Stock · 3,149 shares Expires 2035-05-29 F5 · derivative.exercise_date: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:41 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 2,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015167 · form4-06022025_080616.xml · nonDerivative · entry 2 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,711 F3 · security: Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F4 · balance_after: Includes 4,285 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| May 13, 2025 Filed May 15, 2025 16:33 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | Disposition to issuerStock Options (Right to buy) · Derivative | 24,100 | Not disclosed Strike: $3.93 | Not disclosed |
DisclosureSEC source: 0001562180-25-003880 · primarydocument.xml · derivative · entry 3 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,100 shares Expires not disclosed F4 · kind: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. F4 · price: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. Read SEC document |
| May 13, 2025 Filed May 15, 2025 16:33 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | OtherCommon Stock | 19,510 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-25-003880 · primarydocument.xml · nonDerivative · entry 2 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. Read SEC document |
| May 13, 2025 Filed May 15, 2025 16:33 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | Disposition to issuerCommon Stock | 12,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-25-003880 · primarydocument.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,510 F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F2 · price: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Read SEC document |
| January 02, 2025 Filed Jun 2, 2025 20:41 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 461 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015167 · form4-06022025_080616.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,603 F1 · shares: Represents a grant of restricted stock units received by the Reporting Person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 3,072 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 18:51 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Options (Right to buy) · Derivative | 24,100 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0001562180-24-005006 · primarydocument.xml · derivative · entry 2 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,100 Underlying: Common Stock · 24,100 shares Expires 2034-06-10 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 10, 2025 or the date of the next annual meeting of stockholders of 2seventy bio, Inc. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 18:51 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 12,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005006 · primarydocument.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,560 F1 · security: These restricted stock units vest 100% on the earlier of June 10, 2025 or the date of the next annual meeting of stockholders of 2seventy bio, Inc. Read SEC document |
| May 30, 2024 Filed Jun 4, 2024 00:57 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantStock Option (Right to Buy) · Derivative | 1,246 | $0.00 Strike: $110.70 | $0.00 |
DisclosureSEC source: 0001415889-24-015240 · form4-06042024_120636.xml · derivative · entry 2 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,246 Underlying: Common Stock · 1,246 shares Expires 2034-05-30 F3 · derivative.exercise_date: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date. Read SEC document |
| May 30, 2024 Filed Jun 4, 2024 00:57 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015240 · form4-06042024_120636.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,142 F1 · security: Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 5,841 restricted stock units that have not yet vested or delivery of which has been deferred by the Reporting Person. Read SEC document |
| March 18, 2024 Filed Mar 18, 2024 16:30 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Disposition to issuerOption (right to buy) · Derivative | 1,904 | $92.30 Strike: $237.70 | $175,739.20 |
DisclosureSEC source: 0001140361-24-013934 · form4.xml · derivative · entry 5 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,904 shares Expires 2033-06-19 F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3 · kind: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F3 · price: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F5 · derivative.exercise_date: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date. Read SEC document |
| March 18, 2024 Filed Mar 18, 2024 16:30 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Disposition to issuerOption (right to buy) · Derivative | 5,000 | $227.04 Strike: $102.96 | $1,135,200.00 |
DisclosureSEC source: 0001140361-24-013934 · form4.xml · derivative · entry 4 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2032-06-14 F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3 · kind: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F3 · price: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| March 18, 2024 Filed Mar 18, 2024 16:30 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Disposition to issuerOption (right to buy) · Derivative | 8,500 | $201.99 Strike: $128.01 | $1,716,915.00 |
DisclosureSEC source: 0001140361-24-013934 · form4.xml · derivative · entry 3 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires 2031-06-15 F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3 · kind: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F3 · price: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| March 18, 2024 Filed Mar 18, 2024 16:30 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Disposition to issuerOption (right to buy) · Derivative | 25,000 | $225.74 Strike: $104.26 | $5,643,500.00 |
DisclosureSEC source: 0001140361-24-013934 · form4.xml · derivative · entry 2 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2030-12-21 F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3 · kind: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F3 · price: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| March 18, 2024 Filed Mar 18, 2024 16:30 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Disposition to issuerCommon Stock | 990 | $330.00 | $326,700.00 |
DisclosureSEC source: 0001140361-24-013934 · form4.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F2 · kind: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration. F2 · shares: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration. F2 · price: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:42 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 895 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-000632 · form4-01042024_090140.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,426 F1 · security: Represents a grant of restricted stock units received by the Reporting Person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 6.726 restricted stock units that have not yet vested or delivery of which has been deferred by the Reporting Person. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 16:03 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantOption (right to buy) · Derivative | 1,904 | $0.00 Strike: $237.70 | $0.00 |
DisclosureSEC source: 0000950170-23-029393 · ownership.xml · derivative · entry 2 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,904 Underlying: Common Stock · 1,904 shares Expires 2033-06-19 F2 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 16:03 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantCommon Stock | 990 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-029393 · ownership.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 990 F1 · shares: Comprised of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 17:03 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (right to buy) · Derivative | 16,900 | $0.00 Strike: $11.81 | $0.00 |
DisclosureSEC source: 0001562180-23-005222 · primarydocument.xml · derivative · entry 2 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,900 Underlying: Common Stock · 16,900 shares Expires 2033-06-13 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 13, 2024 or the date of the next annual meeting of stockholders of 2seventy bio, Inc. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 17:03 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 8,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005222 · primarydocument.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,510 F1 · security: These restricted stock units vest 100% on the earlier of June 13, 2024 or the date of the next annual meeting of stockholders of 2seventy bio, Inc. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 00:15 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 3,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009295 · form4-06062023_120658.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,531 F1 · security: Represents a grant of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 10,195 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 01:10 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000469 · form4-01052023_010148.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,301 F1 · security: Represents a grant of restricted stock units received by the Reporting Person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 7,990 restricted stock units that have not vested or been delivered to the Reporting Person. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 16:41 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantOption (right to buy) · Derivative | 5,000 | $0.00 Strike: $102.96 | $0.00 |
DisclosureSEC source: 0001593968-22-001151 · primary_01.xml · derivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 15, 2023, and (ii) the 2023 annual meeting of the Issuer's stockholders. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 18:20 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (right to buy) · Derivative | 16,900 | $0.00 Strike: $13.51 | $0.00 |
DisclosureSEC source: 0001562180-22-004993 · primarydocument.xml · derivative · entry 2 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,900 Underlying: Common Stock · 16,900 shares Expires 2032-06-08 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 8, 2023 or the date of the next annual meeting of stockholders of 2seventy bio, Inc. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 18:20 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 8,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-004993 · primarydocument.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,110 F1 · security: These restricted stock units vest 100% on the earlier of June 8, 2023 or the date of the next annual meeting of stockholder of 2seventy bio, Inc. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-22-036149 · doc4.xml · derivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: The Options shall vest in twelve equal monthly installments following the date of grant or, if earlier, upon the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 23:54 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 4,364 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-068666 · tm2217841-4_4seq1.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,729 F1 · security: Represents a grant of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 10,255 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 18:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001209191-22-001905 · doc4.xml · derivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-01-03 F1 · derivative.exercise_date: The options shall vest in 36 equal monthly installments following December 9, 2021, so long as the grantee remains a director or other service provider of the Company on such dates. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:58 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-001664 · tm221974-4_4seq1.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,365 F1 · security: Represents a grant of restricted stock units received by the reporting person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the F2 · balance_after: Includes 6,916 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:49 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (right to buy) · Derivative | 3,219 | $0.00 Strike: $50.98 | $0.00 |
DisclosureSEC source: 0001628280-21-023474 · wf-form4_163706330477659.xml · derivative · entry 4 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,219 Underlying: Common Stock · 3,219 shares Expires 2031-06-15 F6 · shares: Represents options to purchase shares of 2seventy's common stock granted to the reporting person in connection with the Separation (see footnotes 2 and 3). F8 · derivative.exercise_date: This option vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders (see footnotes 2 and 3). Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:49 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (right to buy) · Derivative | 1,476 | $0.00 Strike: $102.14 | $0.00 |
DisclosureSEC source: 0001628280-21-023474 · wf-form4_163706330477659.xml · derivative · entry 3 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,476 Underlying: Common Stock · 1,476 shares Expires 2030-08-10 F6 · shares: Represents options to purchase shares of 2seventy's common stock granted to the reporting person in connection with the Separation (see footnotes 2 and 3). F7 · derivative.exercise_date: This option vests ratably over three years in annual installments commencing on August 10, 2020 (see footnotes 2 and 3). Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:49 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 2,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023474 · wf-form4_163706330477659.xml · nonDerivative · entry 2 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,910 F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP"), the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date (the "2seventy VWAP") multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: The number of shares underlying the converted 2seventy equity awards was determined by multiplying the number of shares underlying the existing bluebird equity awards by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the sum of (1) the 2seventy VWAP multiplied by the distribution ratio and (2) the quotient obtained by dividing the bluebird Post-Distribution VWAP by the distribution ratio. bluebird equity awards granted on or after January 1, 2021, such equity awards were converted into 2seventy equity awards. The number of shares of 2seventy common stock underlying such converted equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the 2seventy VWAP. F4 · security: In connection with the Separation, the reporting person received restricted stock units, each representing the right to receive a share of 2seventy's common stock, as a result of the adjustment of existing bluebird restricted stock units prior to the Separation (see footnotes 2 and 3). This restricted stock unit award vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. F5 · balance_after: Includes 416 shares of 2seventy's common stock received in a pro rata distribution by bluebird as a result of the Separation. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 06:49 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 492 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023474 · wf-form4_163706330477659.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492 F1 · security: In connection with the separation (the "Separation") of seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"), the reporting person received restricted stock units, each representing the right to receive a share of 2seventy's common stock, as a result of the adjustment of existing bluebird restricted stock units prior to the Separation (see footnotes 2 and 3). This restricted stock unit award vests ratably over three years in annual installments commencing on August 10, 2020. F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP"), the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date (the "2seventy VWAP") multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: The number of shares underlying the converted 2seventy equity awards was determined by multiplying the number of shares underlying the existing bluebird equity awards by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the sum of (1) the 2seventy VWAP multiplied by the distribution ratio and (2) the quotient obtained by dividing the bluebird Post-Distribution VWAP by the distribution ratio. bluebird equity awards granted on or after January 1, 2021, such equity awards were converted into 2seventy equity awards. The number of shares of 2seventy common stock underlying such converted equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the 2seventy VWAP. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:55 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023643 · wf-form4_163715731476743.xml · derivative · entry 4 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2031-06-15 F6 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F6 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F6 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:55 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Disposition to issuerStock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $32.76 | $0.00 |
DisclosureSEC source: 0001628280-21-023643 · wf-form4_163715731476743.xml · derivative · entry 3 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,430 Underlying: Common Stock · 4,430 shares Expires 2030-08-10 F5 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on August 10, 2020 and vests ratably over three years in annual installments commencing on August 10, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F5 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on August 10, 2020 and vests ratably over three years in annual installments commencing on August 10, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F5 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on August 10, 2020 and vests ratably over three years in annual installments commencing on August 10, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:55 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023643 · wf-form4_163715731476743.xml · nonDerivative · entry 2 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,726 F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. F4 · security: Represents restricted stock units awarded to the reporting person prior to the Separation. In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. Read SEC document |
| November 11, 2021 Filed Nov 17, 2021 08:55 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 1,476 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023643 · wf-form4_163715731476743.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,726 F1 · security: Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on August 10, 2020 and vests ratably over three years in annual installments commencing on August 10, 2021. F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 16:16 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $6.10 | $0.00 |
DisclosureSEC source: 0001209191-21-049302 · doc4.xml · derivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2031-08-02 F1 · derivative.exercise_date: The options shall vest ratably over three years following July 6, 2021, so long as the grantee remains a director or other service provider of the Company on such dates. Read SEC document |
| June 16, 2021 Filed Jun 23, 2021 16:37 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantOption (right to buy) · Derivative | 8,500 | $0.00 Strike: $128.01 | $0.00 |
DisclosureSEC source: 0001593968-21-001687 · primary_01.xml · derivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2031-06-15 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 16, 2022, and (ii) the 2022 annual meeting of the Issuer's stockholders. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 16:10 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $32.83 | $0.00 |
DisclosureSEC source: 0001562180-21-004355 · primarydocument.xml · derivative · entry 2 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2031-06-15 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 16:10 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 3,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004355 · primarydocument.xml · nonDerivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,859 F1 · security: These restricted stock units for common stock vest 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.